Dopamine Transporters
Dopamine transporters (DAT) are sodium- and chloride-dependent members of the solute carrier family 6 (SLC6) widely distributed throughout the brain in areas of dopaminergic activity, including the striatum and substantia nigra. They provide rapid clearance of dopamine.
Dopamine Transporter Inhibitors |
|
|---|---|
| Cat. No. | 产品名称/活性 |
| 2831 | Bupropion hydrochloride |
| Non-selective inhibitor of dopamine and noradrenalin transporters | |
| 4798 | (S)-Duloxetine hydrochloride |
| Potent 5-HT and NA reuptake inhibitor; also blocks dopamine reuptake | |
| 0513 | GBR 12783 dihydrochloride |
| Potent and selective DA uptake inhibitor | |
| 0421 | GBR 12909 dihydrochloride |
| Selective DA uptake inhibitor; also σ ligand | |
| 1588 | Indatraline hydrochloride |
| Potent dopamine uptake inhibitor; also inhibits 5-HT and noradrenalin uptake | |
| 4351 | JHW 007 hydrochloride |
| High affinity dopamine uptake inhibitor | |
| 1992 | Nomifensine |
| Potent noradrenalin and dopamine uptake inhibitor. Antidepressant | |
| 2742 | Reserpine |
| Inhibitor of vesicular monoamine transport | |
| 1497 | Rimcazole dihydrochloride |
| DAT inhibitor. Also σ2 antagonist | |
| 2175 | Tetrabenazine |
| Potent inhibitor of vesicular monoamine transport; depletes dopamine stores | |
Other |
|
| Cat. No. | 产品名称/活性 |
| 4946 | AIM 100 |
| Promotes endocytosis and oligomerization of DAT; also Ack1 inhibitor | |
| 5200 | FFN 102 mesylate |
| Selective fluorescent substrate of DAT and VMAT2 | |
Dopamine transporters (DAT) are sodium- and chloride-dependent members of the solute carrier family 6 (SLC6) widely distributed throughout the brain in areas of dopaminergic activity, including the striatum and substantia nigra. They provide rapid clearance of dopamine, adrenalin and noradrenalin from the synaptic cleft, terminating the neurotransmitter signal.
Dopamine transporters can also mediate an outward efflux and it has been suggested that inward and outward transport are independently regulated. Structural motifs include 12-TM domains, extracellular loops, cytoplasmic C- and N-termini and putative phosphorylation sites. There is evidence to support the role of dopamine transporters in attention deficit disorder, bipolar disorder, clinical depression and alcoholism.
External sources of pharmacological information for Dopamine Transporters :
Literature for Dopamine Transporters
Tocris offers the following scientific literature for Dopamine Transporters to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Our Dopamine receptors review gives an overview of the dopamine receptor subtypes, and the receptor agonists and antagonists used to study them.
Request copyRequest PDF
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF